阿托伐他汀联合苯磺酸氨氯地平治疗脑梗死的临床效果研究

Clinical Effect Study of Atorvastatin Combined with Amlodipine on the Treatment of Cerebral Infarction

目的研究脑梗死应用阿托伐他汀与苯磺酸氨氯地平联合治疗的效果。方法将脑梗死患者66例随机分为A组与B组各33例。A组予以常规治疗加苯磺酸氨氯地平,B组在A组治疗基础上加用阿托伐他汀,比较2组疗效。结果治疗后B组的血清总胆固醇(Total cholesterol,TC)、甘油三酯(triglyceride,TG)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)明显低于A组(P<0.05),日常生活能力量表(activity of daily life scale,ADL)评分明显高于A组而美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评分明显低于A组(P<0.05);B组总有效率为93.94%,明显高于A组的78.79%(P<0.05)。A组11例治愈,10例显效,5例有效,7例无效,总有效率为78.79%。B组24例治愈,4例显效,3例有效,2例无效,总有效率为93.94%。B组的有效率明显高于A组(χ2=8.501,P=0.003<0.05)。结论阿托伐他汀与苯磺酸氨氯地平联合治疗脑梗死能够调节血脂代谢、改善神经功能缺损及生活活动能力、提高临床疗效。

Objective To study the effect of atorvastatin combined with amledipine on the treatment of cerebral infarction. Methods 66 patients with cerebral infarction were randomly divided into group A and group B, 33 cases for each group. The group A was given conventional treatment with amlodipine, the group B was treated with atorvastatin on the basis of group A, the curative effect of the two groups were compared. Results The TC, TG and LDL-C in group B were significantly lower than that of group A after treatment （P〈 0.05）, the ADL score was significantly higher than that of group A but the NIHSS score was obviously lower than that of group A （P〈0.05）; the rate of total effective of group B was 93.94%, which was remarkably higher than that of group A which was 78.79%（P〈0.05）. In group A, 11 cases were cured, 10 cases were markedly effective, 5 cases were effective, 7 cases were ineffective, the total effective rate was 78.79%. In group B, 24 cases were cured, 4 cases were markedly effective, 3 cases were effective, 2 cases were ineffective, the total effective rate was 93.94%. The effective rate of group B was significantly higher than that of group A （X2=8.501, P=0.003 〈0.05）. Conclusion Atorvastatin combined with amledipine in the treatment of cerebral infarction can regulate blood lipid metabolism, improve neurological function defect, life activity ability and improve clinical efficacy.